{"id":5872,"date":"2017-02-08T15:32:26","date_gmt":"2017-02-08T04:32:26","guid":{"rendered":"https:\/\/blogs.rch.org.au\/news\/?p=5872"},"modified":"2017-02-09T10:33:56","modified_gmt":"2017-02-08T23:33:56","slug":"12-month-old-kumail-defies-the-odds","status":"publish","type":"post","link":"https:\/\/blogs.rch.org.au\/news\/12-month-old-kumail-defies-the-odds\/","title":{"rendered":"12-month-old Kumail defies the odds"},"content":{"rendered":"<div class=\"tg-tlc-storybody_intro\">\n<p><em>First published in the Herald Sun February 8, 2017<\/em><\/p>\n<p><em>Words by Brigid O&#8217;Connell<\/em><\/p>\n<p>Physiotherapists cried when they saw baby Kumail Wakil at his last check-up.<\/p>\n<p>After he was diagnosed with Spinal muscular atrophy &#8211; the childhood version of Motor Neurone Disease &#8211; they expected his whole body to be floppy and him struggling to breathe.<\/p>\n<p>Kumail\u2019s eight-year-old sister Rubab was in a wheelchair at his age from a less severe form of the same incurable and progressive condition.<\/p>\n<figure id=\"attachment_5874\" aria-describedby=\"caption-attachment-5874\" style=\"width: 400px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-5874\" src=\"https:\/\/blogs.rch.org.au\/news\/files\/2017\/02\/Kumail-4-400x267.jpg\" alt=\"Photo: Jason Edwards\/Herald Sun\" width=\"400\" height=\"267\" srcset=\"https:\/\/blogs.rch.org.au\/news\/files\/2017\/02\/Kumail-4-400x267.jpg 400w, https:\/\/blogs.rch.org.au\/news\/files\/2017\/02\/Kumail-4-768x512.jpg 768w, https:\/\/blogs.rch.org.au\/news\/files\/2017\/02\/Kumail-4-800x533.jpg 800w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><figcaption id=\"caption-attachment-5874\" class=\"wp-caption-text\">Photo: Jason Edwards\/Herald Sun<\/figcaption><\/figure>\n<p>Instead, after he became the first Australian child to be given compassionate access to a new gene therapy at the Royal Children\u2019s Hospital as a six-week-old &#8211; before he started showing symptoms &#8211; therapists saw a strong and healthy 12-month-old who has so far reached all his developmental milestones.<\/p>\n<p>The international trial of the drug Spinraza was stopped halfway through in October when interim results stunned doctors, and it was only ethical to also give the drug to those on placebo.<\/p>\n<p>RCH\u2019s director of neurology, Professor Monique Ryan said the drug\u2019s \u201cdramatic\u201d effects should give hope to the 10 Victorian children born each year with the most severe Type 1, for which affected children usually don\u2019t reach their third birthday.<\/p>\n<p>\u201cI\u2019ve been involved in lots of neuromuscular trials over the years, and sometimes you find something that works a bit. But this was a different experience,\u201d Prof Ryan said.<\/p>\n<p>\u201cI\u2019ve never been involved in a trial like this where it is completely obvious that it is working.<\/p>\n<p>\u201cIt\u2019s early days, but these were babies who are clearly becoming stronger and obtaining milestones we have not seen babies with this condition obtain before.\u201d<\/p>\n<p>The spinal cord injection, given every four months after an initial loading period, aims to replace to missing survival motor neuron protein that is critical for the nerves that control muscles.<\/p>\n<p>Mohammad Wakil said while they feared the worst for their son after already seeing their daughter struggle, they could hardly believe their eyes when Kumail started gaining strength.<\/p>\n<p>\u201cOur hope was not pretty strong when he was born. But as time past, we saw he was crawling, he was moving his arms and legs as a normal child,\u201d Mr Wakil said.<\/p>\n<p>\u201cThe main thing we wish is for him to stand on his feet and to have a healthy life.\u201d<\/p>\n<p>While the drug is not a cure, Prof Ryan said the hope was that Spinraza could buy children time for the next iterations of this medication, and to be used in combination with other promising drugs, to further improve their quality and length of life.<\/p>\n<p>The extended access program will allow RCH patients with Type 1 to access it as needed, with some children with the less severe Type 2 to also receive it this year.<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Find out how Prof Monique Ryan and her team helped Kumail defy the odds with a spinal muscular atrophy wonder drug.<\/p>\n","protected":false},"author":66,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8971,6],"tags":[],"class_list":["post-5872","post","type-post","status-publish","format-standard","hentry","category-featured","category-in-the-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/posts\/5872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/users\/66"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/comments?post=5872"}],"version-history":[{"count":4,"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/posts\/5872\/revisions"}],"predecessor-version":[{"id":5877,"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/posts\/5872\/revisions\/5877"}],"wp:attachment":[{"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/media?parent=5872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/categories?post=5872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.rch.org.au\/news\/wp-json\/wp\/v2\/tags?post=5872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}